CABA highlights rese-cel CAR-T safety and nine-day manufacturing process
Cabaletta’s rese-cel team cited a nine-day manufacturing process and strong safety profile, reporting over 90 patients treated with no IEC-HS events. Expansion into scleroderma and myositis is underway with dual manufacturing partnerships.
The team highlighted rese-cel’s nine-day manufacturing process and a strong safety profile, saying more than 90 patients have been treated and there have been no IEC-HS events. Expansion into scleroderma and myositis is under way, with dual manufacturing partnerships aimed at supporting scalability and cost efficiency.